Fiche centre
Novartis Investigative Site
Heidelberg — Australia
Essais liés4clinical trials
VilleHeidelberglocalisation
PaysAustralialocalisation
SourcelocaleCSV/MySQL
Informations
centreSynchronisé depuis ClinicalTrials.gov — NCT07094516
Essais cliniques associés
4| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| Inclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL | Maladie coronarienne | Phase 3 | NCT05739383 | A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients. | ACTIVE_NOT_RECRUITING |
| VHB937 | Alzheimer | Phase 2 | NCT07094516 | A Clinical Trial to Learn About the Effects of VHB937 in People With Early Alzheimer's Disease | ACTIVE_NOT_RECRUITING |
| Remibrutinib (Blinded) | SEP | Phase 3 | NCT07225504 | REMASTER — A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis | RECRUITING |
| EAFToS — Characterizing the Use of Ofatumumab in a Real World Setting | SEP | À vérifier | NCT05090033 | EAFToS — Characterizing the Use of Ofatumumab in a Real World Setting | COMPLETED |